Immune Modulation in Sepsis, ARDS, and Covid-19 - The Road Traveled and the Road Ahead

Leligdowicz et al. consider the history and future of immunomodulating therapies in sepsis and ARDS, including ARDS due to Covid-19, and remark on the larger challenge of clinical research on therapies for syndromes with profound clinical and biologic heterogeneity.